Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03915626 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Heat on Rivastigmine TDS Products
A Early Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT03915626 is a Early Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 7 participants.
The verdict
NCT03915626, a Early Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This research study is designed to measure the amount of medicine in blood over time after the patch is placed on the skin with and without external heat application.
Interventions
- DRUG Rivastigmine (RLD) transdermal patch
- DRUG Rivastigmine (generic) transdermal patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-10-04 |
| Est. Completion | 2021-05-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03915626
The ClinicalTrials.gov registry entry for NCT03915626 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rivastigmine (RLD) transdermal patch is the first listed.
NCT03915626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03915626 about?
NCT03915626 is a clinical study titled "Effect of Heat on Rivastigmine TDS Products". This research study is designed to measure the amount of medicine in blood over time after the patch is placed on the skin with and without external heat application.
What is the current status of trial NCT03915626?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2019-10-04. Estimated completion is 2021-05-04.
What interventions are being tested in trial NCT03915626?
The interventions under investigation include: Rivastigmine (RLD) transdermal patch (DRUG), Rivastigmine (generic) transdermal patch (DRUG).
Who is sponsoring clinical trial NCT03915626?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.